# India AMR Co-Development Programme (I-AMR-CDP) > Accelerating Indian Anti-Infective Innovations from Lab to Patient. This is a text version of the single-page programme website, generated from the same content at build time. It is programme information, not medical advice. ## Overview A translational and co-development pathway designed to identify and advance promising antibacterial innovations emerging from India. Accelerating Indian Anti-Infective Innovations from Lab to Patient. Led by Venus Remedies Limited. AMR means antimicrobial resistance. This is an industry-led co-development programme for antibacterial therapeutics for human health in India. A development and commercialisation partner — not a funding programme. India has scientific talent, research institutions and promising innovations, but many promising ideas face a gap between discovery, development, clinical translation and patient impact. I-AMR-CDP is designed to help bridge that gap. ## Pathway From promising science to patient impact 1. **Identify:** Find promising innovations. 2. **Evaluate:** Scientific and development assessment. 3. **Develop:** Preclinical, CMC, formulation and other development activities as appropriate. 4. **Translate:** Clinical, regulatory and manufacturing development. 5. **Commercialise:** Progress viable innovations towards patients. 1. **India has the science:** India has a strong scientific talent base, established research institutions and promising antibacterial innovations. The challenge is helping these innovations progress from discovery towards development and patient impact. 2. **I-AMR-CDP bridges the gap:** Promising molecules can stall between discovery and patient impact. I-AMR-CDP bridges development and clinical translation — preclinical, CMC, formulation, clinical, regulatory and manufacturing — to help them progress. 3. **From lab to patient:** Carried across the bridge, promising Indian antibacterial innovations can reach the patients who need them. ## Eligibility Built for the people doing India’s AMR science - Academia: Indian universities, institutes and research organisations. - Startups & Biotech: Indian companies developing relevant innovations. - Researchers: Indian scientists and translational research teams. - Innovation Teams: Teams developing promising antibacterial / anti-infective approaches. Focus: Antibacterial therapeutics for human health. - Novel antibiotics - β-lactamase inhibitors - Adjunctive / potentiator therapies - Stage: Proof-of-concept, any preclinical stage, or later. - Need: Clinically relevant AMR pathogens or unmet medical needs — WHO or Indian Priority Pathogens List (IPPL) targets. - Novelty: Scientific novelty supported by publications and/or filed patents. Pathogen examples: Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli. Out of scope: Diagnostics, disinfectants, vaccines, antifungals, antivirals and early exploratory discovery projects. This describes the published criteria; only the programme team can determine eligibility and selection. ## Application Apply through the [official Microsoft Forms application](https://forms.cloud.microsoft/pages/responsepage.aspx?id=2zqs2kcqwkK1vPmHAn-bzCXzLry5rilCjlhOE2kxKpBUMVZJVUVQQjk1NkxXMFdKWllVQVpDSkE5My4u&route=shorturl). Deadline displayed on the website: 31 October 2026 (2026-10-31). Confirm current dates and requirements on the linked application form or with the programme contact before applying. - No confidential information is required at application stage. - Confidential discussions happen only after shortlisting, under a CDA. - Your IP remains yours unless agreed otherwise. The website links to an external form. It does not accept or submit applications itself. ## Process A structured path from application to development 1. **Submit:** Initial non-confidential application. 2. **Screen:** Eligibility and programme-fit assessment. 3. **Evaluate:** Scientific and development review. 4. **Select:** Shortlisted candidates move into detailed discussions. 5. **Co-develop:** Selected candidates enter an appropriate project-specific development pathway. ## Support - INR 10 lakh upfront award: For selected candidates, upon entering a co-development agreement. - End-to-end development investment: Translational studies, preclinical development, CMC, PK/PD, regulatory submissions and clinical studies — as appropriate to the stage of the asset. - Direct scientific engagement: With Venus R&D scientists and domain experts across microbiology, PK/PD, toxicology, formulation, analytical, regulatory, clinical, IPR, manufacturing and BD. - Advanced R&D infrastructure: Access to Venus laboratories for validation and development work, subject to feasibility and mutual agreement. - IP & publication support: Guidance on patent strategy, freedom-to-operate considerations and aligned publication planning. - Commercialisation pathway: Venus Remedies leads manufacturing and commercialisation under mutually agreed terms. All support is governed through appropriate agreements, with no change in IP ownership or rights unless explicitly agreed as part of a formal co-development agreement. Venus Remedies leads and invests in the development pathway for selected candidates, with project-specific terms agreed with applicants. Support and selection are subject to review and project-specific agreements. ## Partners - **Venus Remedies Limited — Programme Lead & Co-Development Partner:** Leads and invests in development, manufacturing and commercialisation. - **ADVANCE-ID Network — Clinical Research Partner:** Global infectious disease clinical trials network — 50+ hospitals, 20 countries. - **GARDP — Knowledge Partner:** Not-for-profit created by WHO and DNDi to tackle drug-resistant infections. - **EDDC — Translational Development Advisory Partner:** Singapore’s national platform for drug discovery and development. - **Office of the Principal Scientific Adviser to the Government of India — Ecosystem Outreach Partner:** Advises the Government of India on science, technology and innovation. - **Manthan — Ecosystem Outreach Partner:** Ideas and implementation through science, technologies and innovations. ## Capabilities Industry-led development beyond discovery - Preclinical: Preclinical pharmacology and toxicology, with microbiology and AMR research in-house. - PK/PD: PK/PD and translational sciences, including the Hollow-Fiber Infection Model. - CMC & Formulation: Process development, CMC, formulation and drug-delivery sciences. - Clinical Development: Clinical interface, medical writing and medical affairs. - Regulatory: Regulatory strategy and submissions, backed by quality systems. - Manufacturing: India’s largest exporter of critical care antibiotics, including meropenem. - Commercialisation: A global presence across 100+ countries. Venus Remedies Limited is a research-driven Indian pharmaceutical company with a global presence in 100+ countries, focused on complex and life-threatening diseases — particularly in critical care and anti-infectives. The company is widely recognised for its leadership in AMR, supported by sustained investment in advanced R&D, patented therapies and translational science. Through its dedicated research arm, Venus Medicine Research Centre, it runs a fully integrated R&D ecosystem that bridges the bench to the bedside — including advanced platforms such as the Hollow-Fiber Infection Model and Human Organ-on-a-Chip. - Lead & invest: Venus leads and invests in the development pathway for selected candidates. - Develop: Translational, preclinical, CMC, PK/PD, regulatory and clinical work — as the asset requires. - Manufacture: Production backed by India’s largest exporter of critical care antibiotics. - Commercialise: Taking viable innovations to patients, across a presence in 100+ countries. ## Perspectives > The India AMR Co-Development Programme is a meaningful step toward supporting the development of India’s antimicrobial innovations. Such collaborative efforts are important in addressing the growing challenge of antimicrobial resistance in the country. — Prof. Ajay Sood, Principal Scientific Adviser to the Government of India > The collaboration between ADVANCE-ID and the India AMR Co-Development Programme reflects the importance of integrating clinical development perspectives early in the translational pathway of antibacterial innovation. Such partnerships can play an important role in strengthening the development of clinically relevant AMR solutions. — Prof. David Paterson, Director, ADVANCE-ID The ADVANCE-ID Network (Advancing Clinical Evidence in Infectious Diseases) is a global infectious disease clinical trials network headquartered at the National University of Singapore — over 50 hospitals across 20 countries conducting high-quality clinical research, with a strong localised footprint across Asia, including India. For I-AMR-CDP, ADVANCE-ID brings clinical development perspectives into the translational pathway early. [ADVANCE-ID](https://www.advance-id.network/) > Addressing antimicrobial resistance requires collaboration across the healthcare ecosystem. We are pleased to support India AMR Co-Development Programme as a Knowledge Partner and contribute scientific, strategic, and global AMR perspectives to the programme. Initiatives such as this help foster collaboration and strengthen efforts to address the growing challenge of AMR through innovation and partnership. — Karan Prabhakar, Head of Product Delivery & India Office, GARDP GARDP (Global Antibiotic Research and Development Partnership) is a not-for-profit organisation created by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi). Its mission is to protect people from the rise and spread of drug-resistant infections — work made possible by collaboration with over 100 R&D and access partners in over 20 countries. As Knowledge Partner, GARDP contributes scientific, strategic and global AMR perspectives to the programme. [GARDP](https://gardp.org/) > EDDC is honoured to serve as the Translational Development Advisory Partner for the India AMR Co-development Programme (I-AMR-CDP), bridging scientific innovation and translational development to help bring much-needed AMR solutions closer to patients. — Dr. Kantharaj Ethirajulu, Director, Asset Development, EDDC The Experimental Drug Development Centre (EDDC) is Singapore’s national platform for drug discovery and development. Formed in 2019 from three publicly funded entities, it integrates small and large molecule discovery, preclinical development, CMC, and regulatory and clinical development capabilities to translate innovative discoveries into impactful treatments. As Translational Development Advisory Partner, EDDC offers advisory perspective on translational development. [EDDC](https://www.eddc.sg/) ## Leadership Venus Remedies is not merely hosting this programme. Venus is committed to developing the innovations that emerge from it. Mr. Saransh Chaudhary: Executive Director, Venus Remedies Limited; CEO, Venus Medicine Research Centre. The leadership quotation is awaiting editorial approval and is excluded from this mirror. > India has a strong scientific talent base and a growing pipeline of promising anti-infective innovations. I-AMR-CDP is designed to create the translational pathway needed to take these innovations beyond discovery and towards clinical and patient impact. — Anmol Aggarwal, Programme Lead, I-AMR-CDP ## Voices > Antibiotics are indispensable, life saving drugs that form the bedrock of modern medicine. But their efficacy is compromised by antimicrobial resistance (AMR). Investment in R&D for novel antibiotics is an urgent and pressing need. The India AMR Co-Development Programme is a significant step in this direction. — Dr. Radha Rangarajan, Director, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow > Overcoming AMR requires more than scientific breakthroughs; it requires an ecosystem that enables innovation to flourish. By fostering collaboration between academia, industry, funders, and health systems, initiatives such as the India AMR Co-Development Programme can accelerate the development of new antimicrobial solutions and help ensure they reach those most affected by drug-resistant infections. — Ghada Zoubiane, Senior Director, Global Health Infection, LifeArc; Trustee, AMR Action UK > A core challenge in AMR is ensuring that promising antibacterial research can progress toward practical use. Strong innovation ecosystems are central to this, creating the connections and capabilities needed for sustained development. Programmes like the India AMR Co-Development Programme help reinforce these conditions and support a more enabling environment for antimicrobial innovation. — Lesley Ogilvie, Director, Global AMR R&D Hub > The AMR race is often described as a contest between humans and microbes. It is not. It is a race between the speed of evolution and the speed of innovation. Unless we build ecosystems that innovate as rapidly as resistance evolves, we will always be responding to yesterday’s threat. > > Initiatives like the India AMR Co-Development Programme are critical to bridging the gap between discovery and impact by creating a seamless pathway from innovation to validation, adoption and scale. Encouraging such collaborative platforms will ensure that the next breakthrough reaches patients before the next resistant pathogen does. — Dr. Swetavalli Raghavan, Advisor on AMR, Government of Karnataka > The fight against AMR will be won through collaboration that transforms scientific discovery into public health impact. By fostering a strong translational ecosystem, the India AMR Co-Development Programme can accelerate Indian innovations from the laboratory to the patient’s bedside, strengthening India’s leadership in developing affordable antimicrobial solutions for the Global South and beyond. — Dr. Ranga Reddy Burri, President, Infection Control Academy of India (IFCAI); President, Antimicrobial Resistance Research Society of India (AMRRSI) > Antimicrobial resistance (AMR) is a complex challenge that can only be effectively tackled through collaboration among all stakeholders. One of the most important solutions is the development of new antibacterial therapies. The India AMR Co-Development Programme (I-AMR-CDP) is an excellent initiative that will strengthen India’s antibacterial innovation ecosystem by helping translate promising research into therapies that can benefit patients. — Dr. Abdul Ghafur, Consultant & Adjunct Professor, Infectious Diseases, Apollo Hospitals, Chennai; Coordinator, Chennai Declaration on AMR > Innovation is key to tackling the challenges facing the world. Mitigating the AMR challenge through innovation therefore is paramount if we are to sustain life as we know it. Let’s do our part through collaborative innovation, not just for ourselves, but for the generations to come! — Dr. Sujith J. Chandy, Senior Professor, Christian Medical College (CMC), Vellore Quotations marked as placeholders in the source are excluded from this mirror until approved. ## Updates Application count displayed on the website: 26. This is a published snapshot, not a live counter. AMR innovation is emerging across India. Every application represents a team working to address an important challenge in antimicrobial resistance. - Milestone — Applications arrive from across India: Applications reached the open call from across the country within just a few weeks. - Partner — EDDC joins as Translational Development Advisory Partner: Singapore’s national platform for drug discovery and development joins the programme. - Partner — GARDP joins as Knowledge Partner: Contributing scientific, strategic and global AMR perspectives to the programme. - Partner — ADVANCE-ID joins as Clinical Research Partner: A global infectious disease clinical trials network of 50+ hospitals across 20 countries. ## Contact Programme contact: Anmol Aggarwal, R&D Strategy, Venus Remedies. Email: [anmolaggarwal@venusremedies.com](mailto:anmolaggarwal@venusremedies.com). [Venus Remedies](https://venusremedies.com) [Privacy policy](https://venusremedies.com/privacypolicy) ## Website navigation - [Programme](/#psa) - [Why I-AMR-CDP](/#why) - [How It Works](/#how) - [Who Can Apply](/#who) - [Partners](/#partners) - [Voices for AMR](/#voices) ## Agent access - [Discovery index](/llms.txt) - [Structured programme information](/programme.json) - Compatible browsers expose read-only WebMCP tools named get_programme_information and get_application_details. - There is no application submission, account, payment, or confidential-data API on this website.